keyword
MENU ▼
Read by QxMD icon Read
search

ABVD

keyword
https://www.readbyqxmd.com/read/28295527/factors-predicting-survival-in-chronic-lymphocytic-leukemia-patients-developing-richter-syndrome-transformation-into-hodgkin-lymphoma
#1
Francesca Romana Mauro, Piero Galieni, Alessandra Tedeschi, Luca Laurenti, Giovanni Del Poeta, Gianluigi Reda, Marina Motta, Alessandro Gozzetti, Roberta Murru, Maria Denise Caputo, Melissa Campanelli, Anna Maria Frustaci, Idanna Innocenti, Sara Raponi, Anna Guarini, Fortunato Morabito, Robin Foà, Massimo Gentile
We hereby report the clinical and biologic features of 33 of 4680 (0.7%) patients with chronic lymphocytic leukemia (CLL), managed at 10 Italian centers, who developed Hodgkin lymphoma (HL), a rare variant of Richter syndrome. The median age at CLL and at HL diagnosis were 61 years (range 41-80) and 70 years (range 46-82), respectively, with a median interval from CLL to the diagnosis of HL of 90 months (range 0-258). In 3 cases, CLL and HL were diagnosed simultaneously. Hl was characterized by advanced stage in 79% of cases, International Prognostic Score (IPS) ≥4 in 50%, extranodal involvement in 39%, B symptoms in 70%...
March 10, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28291393/early-positron-emission-tomography-response-adapted-treatment-in-stage-i-and-ii-hodgkin-lymphoma-final-results-of-the-randomized-eortc-lysa-fil-h10-trial
#2
Marc P E André, Théodore Girinsky, Massimo Federico, Oumédaly Reman, Catherine Fortpied, Manuel Gotti, Olivier Casasnovas, Pauline Brice, Richard van der Maazen, Alessandro Re, Véronique Edeline, Christophe Fermé, Gustaaf van Imhoff, Francesco Merli, Réda Bouabdallah, Catherine Sebban, Lena Specht, Aspasia Stamatoullas, Richard Delarue, Valeria Fiaccadori, Monica Bellei, Tiana Raveloarivahy, Annibale Versari, Martin Hutchings, Michel Meignan, John Raemaekers
Purpose Patients who receive combined modality treatment for stage I and II Hodgkin lymphoma (HL) have an excellent outcome. Early response evaluation with positron emission tomography (PET) scan may improve selection of patients who need reduced or more intensive treatments. Methods We performed a randomized trial to evaluate treatment adaptation on the basis of early PET (ePET) after two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in previously untreated-according to European Organisation for Research and Treatment of Cancer criteria favorable (F) and unfavorable (U)-stage I and II HL...
March 14, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28236527/-primary-osseous-hodgkin-s-lymphoma-of-the-sacrum-a-diagnostic-and-therapeutic-challenge
#3
N Fourati, S Kanoun Belajouza, H Regaieg, A Khlif, N Bouaouina
Primary osseous Hodgkin's lymphoma is a very rare entity. Cases reported in the literature are limited with often insufficient initial exploration. We report a new case of a 24 years old patient with a diagnosis of primary osseous Hodgkin lymphoma of the lumbosacral region with extension to the soft tissues, without simultaneous lymph node involvement confirmed both by conventional and metabolic imaging. The patient received a combination chemotherapy (two courses BEACOPP(®) and four courses ABVD) followed by radiotherapy of the lombosacral region at the dose of 40Gy in 20 fractions...
February 21, 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/28197347/hodgkin-lymphoma-and-castleman-disease-when-one-blood-disease-can-hide-another
#4
L Filliatre-Clement, H Busby-Venner, C Moulin, G Roth-Guepin, A Perrot
We describe a rare case of Castleman disease associated de novo with Hodgkin lymphoma. The incidence of Castleman disease is rare; only a few studies have described it in de novo association with Hodgkin lymphoma. The patient described here complained of unique evolutionary axillary adenopathy. A positron-emission tomography/computed tomography scan revealed hypermetabolic activity in this area. Diagnosis was based on a total excision biopsy of the adenopathy. The patient underwent complete remission with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy for treating Hodgkin lymphoma after surgical excision of the unicentric Castleman disease lesion...
2017: Case Reports in Hematology
https://www.readbyqxmd.com/read/28126883/prognostic-value-of-bone-marrow-tracer-uptake-pattern-in-baseline-pet-scan-in-hodgkin-lymphoma-results-from-an-international-collaborative-study
#5
Colette Zwarthoed, Tarec Cristoffer El-Galaly, Maria Canepari, Matthieu John Ouvrier, Julien Viotti, Marc Ettaiche, Simonetta Viviani, Luigi Rigacci, Livio Trentin, Chiara Rusconi, Stefano Luminari, Maria Cantonetti, Silvia Bolis, Anna Borra, Jacques Darcourt, Flavia Salvi, Edyta Subocz, Joanna Tajer, Waldemar Kulikowski, Bogdan Malkowski, Jan Maciej Zaucha, Andrea Gallamini
RATIONALE: Positron Emission Tomography/Computed Tomography (PET/CT)-ascertained bone marrow involvement (BMI) constitutes the single most important reason for upstaging by PET/CT in Hodgkin lymphoma (HL). However, BMI assessment in PET/CT can be challenging. This study analysed the clinico-pathological correlations and prognostic meaning of different patterns of bone marrow (BM)-Fluorodeoxyglucose (FDG)-uptake in HL. PATIENTS AND METHODS: 180 newly diagnosed early unfavourable and advanced stage HL patients, all scanned at baseline and after 2 Adriamycin-Bleomycin-Vinblastine-Dacarbazine (ABVD) courses with FDG-PET, enrolled in two International studies aimed at assessing the role of interim PET scan in HL, were retrospectively included...
January 26, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28042455/differences-in-outcome-of-patients-with-syncytial-variant-hodgkin-lymphoma-compared-with-typical-nodular-sclerosis-hodgkin-lymphoma
#6
Tarsheen Sethi, Van Nguyen, Shaoying Li, David Morgan, John Greer, Nishitha Reddy
BACKGROUND: Nodular sclerosis Hodgkin lymphoma (NS-HL) is the most common subtype of HL and usually has a good prognosis. A variant of NS, the syncytial variant (SV) has well-established histopathologic features but little is known about its clinical behavior. Small case series have suggested that SV patients present with advanced disease and have a comparatively aggressive course. The objective of this study was to determine the clinical characteristics and outcome of SV patients. METHODS: A total of 167 adult patients with NS-HL including 43 patients with SV and 124 patients with typical NS (t-NS) were included in our analysis following institutional review board (IRB) approval...
January 2017: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/27928934/letter-in-reply-to-fertility-preservation-before-an-abvd-protocol-no-new-evidence-to-support-changing-the-recommendations
#7
LETTER
Charlotte Sonigo, Nathalie Sermondade, Michaël Grynberg
No abstract text is available yet for this article.
March 2017: Future Oncology
https://www.readbyqxmd.com/read/27923859/non-growing-follicle-density-is-increased-following-adriamycin-bleomycin-vinblastine-and-dacarbazine-abvd-chemotherapy-in-the-adult-human-ovary
#8
M McLaughlin, T W Kelsey, W H B Wallace, R A Anderson, E E Telfer
STUDY QUESTION: Do the chemotherapeutic regimens of ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) or OEPA-COPDAC (combined vincristine, etoposide, prednisone, doxorubicin (OEPA) and cyclophosphamide, vincristine, prednisone, dacarbazine (COPDAC)) used to treat Hodgkin lymphoma (HL), affect the density, morphology and in vitro developmental potential of human ovarian follicles? SUMMARY ANSWER: Ovarian tissue from women treated with ABVD contained a higher density of non-growing follicles (NGFs) per cubic millimetre and increased numbers of multiovular follicles but showed reduced in vitro growth compared with patients with lymphoma who had not received chemotherapy, patients treated with OEPA-COPDAC, age-matched healthy women and age-related model-predicted values...
January 2017: Human Reproduction
https://www.readbyqxmd.com/read/27921440/fertility-preservation-before-an-abvd-protocol-no-new-evidence-to-support-changing-the-recommendations
#9
LETTER
Catherine Poirot, Nathalie Dhedin, Pauline Brice
No abstract text is available yet for this article.
March 2017: Future Oncology
https://www.readbyqxmd.com/read/27919174/outcome-of-pediatric-advanced-hodgkin-lymphoma-treated-with-abvd-and-predictors-of-inferior-survival-a-multicenter-study-of-186-patients
#10
Sainath Bhethanabhotla, Sandeep Jain, Gauri Kapoor, Amita Mahajan, Anita Chopra, Sreenivas Vishnubhatla, Sameer Bakhshi
Clinical stage alone is used for risk stratification in treatment of pediatric advanced Hodgkin lymphoma (HL). To identify other risk factors, we collected data from three tertiary centers on 186 patients with advanced stage (IIB-IV) consecutively treated with Adriamycin, bleomycin, vinblastine, Dacarbazine (ABVD) chemotherapy ± radiotherapy. Freedom from treatment failure (FFTF) and overall survival (OS) were end points. With median follow-up period of 57.9 months (range: 1-151 months), five-year FFTF and OS was 84...
December 6, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27913497/response-adapted-frontline-therapy-for-hodgkin-lymphoma-are-we-there-yet
#11
Peter W M Johnson
Treating Hodgkin lymphoma by using chemotherapy with or without radiotherapy is highly successful, with substantially fewer deaths from lymphoma than from other causes in recent studies of both early-stage and advanced-stage disease. Long-term toxicity is a major consideration in this context, and recent trials have used functional imaging with [(18)F]fluorodeoxyglucose (FDG) positron emission tomography early in the course of treatment (interim PET) to assess response and modulate subsequent therapy. In early-stage disease, this has allowed omission of consolidation radiotherapy after a good response to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy, and trials have shown that this can be done without detriment to overall survival, despite a small increase in rates of recurrence of ∼5%...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27812252/chemotherapy-and-radiation-induced-pulmonary-dysfunction-in-hodgkin-lymphoma-patients
#12
Sebnem Izmir Guner, Mustafa Teoman Yanmaz, Ahmet Selvi, Cigdem Usul
Although the deterioration in pulmonary functions is a well-known important problem due to the treatment of the Hodgkin's lymphoma patients, the immediate and long term effects of the therapy and its distinctive components were not shown clearly yet. We planned to investigate effects of multiple agent chemotherapy and/or radiotherapy to pulmonary functions immediately and thereafter and the possible effects of the managing this situation. 34 patients were included the study. The patients were evaluated for peak expiratory flow (PEF), forced expiratory volume in 1 s (FEV1), forced expiratory vital capacity (FVC), mean total lung capacity (TLC) values, FEV1/FVC ratio, diffusing capacity for carbonmonoxide (DLco), diffusing capacity for carbonmonoxide corrected for hemoglobin concentration (DLCO) before and at 1, 6 and 12 months after the initiation of the treatment...
December 2016: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/27810161/impact-of-hodgkin-or-non-hodgkin-lymphoma-and-their-treatments-on-sperm-aneuploidy-a-prospective-study-by-the-french-cecos-network
#13
Guillaume Martinez, Marie Walschaerts, Marine Le Mitouard, Remi Borye, Claire Thomas, Jacques Auger, Isabelle Berthaut, Florence Brugnon, Myriam Daudin, Nathalie Moinard, Célia Ravel, Jacqueline Saias, Ethel Szerman, Nathalie Rives, Sylviane Hennebicq, Louis Bujan
OBJECTIVE: To assess sperm production and aneuploidy in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) before and after treatments. DESIGN: Multicenter, prospective, longitudinal study of lymphoma patients analyzed before treatment and after 3, 6, 12, and 24 months. SETTING: University hospitals. PATIENT(S): Forty-five HL and 13 NHL patients were investigated before and after treatment. Treatment regimens were classified in two groups: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) with or without (±) radiotherapy, and CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)/MOPP-ABV (mechlorethamine, oncovin, procarbazine, prednisone-doxorubicin, bleomycin, vinblastine)...
February 2017: Fertility and Sterility
https://www.readbyqxmd.com/read/27758822/mediastinal-gray-zone-lymphoma-clinico-pathological-characteristics-and-outcomes-of-99-patients-from-the-lymphoma-study-association
#14
Clémentine Sarkozy, Thierry Molina, Hervé Ghesquières, Anne-Sophie Michallet, Jehan Dupuis, Diane Damotte, Franck Morsschauser, Marie Parrens, Laurent Martin, Peggy Dartigues, Aspasia Stamatoullas, Pierre Hirsch, Bettina Fabiani, Krimo Bouabdallah, Maria Gomes da Silva, Marie Maerevoet, Camille Laurent, Bertrand Coiffier, Gilles Salles, Alexandra Traverse-Glehen
Mediastinal gray zone lymphoma, B-cell lymphomas with intermediate features between classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma, have not been well described in the literature. We report the clinical characteristics and outcomes of a large retrospective series of 99 cases centrally reviewed by a panel of hematopathologists, with a consensus established for the diagnosis. Cases were defined as classical Hodgkin lymphoma-like morphology (64.6%) with primary mediastinal B-cell lymphoma immunophenotype, primary mediastinal B-cell lymphoma-like morphology (30...
January 2017: Haematologica
https://www.readbyqxmd.com/read/27754902/post-treatment-pet-ct-rather-than-interim-pet-ct-using-deauville-criteria-predicts-outcome-in-pediatric-hodgkin-lymphoma-a-prospective-study-comparing-pet-ct-versus-conventional-imaging
#15
Sameer Bakhshi, Sainath Bhethanabhotla, Rakesh Kumar, Krishankant Agarwal, Punit Sharma, Sanjay Thulkar, Arun Malhotra, Deepa Dhawan, Sreenivas Vishnubhatla
BACKGROUND: Data about significance of (18)F-FDG positron emission tomography (PET) at interim assessment and end of treatment in pediatric Hodgkin lymphoma (HL) are limited. METHODS: Patients (≤18 years) with HL were prospectively evaluated with contrast-enhanced computed tomography (CECT) and PET combined with low-dose CT(PET-CT) at baseline, post 2 cycles of chemotherapy and post completion of treatment. Revised international working group criteria (RIW) and Deauville (DA) five point-scale for response assessment by PET-CT were used...
October 6, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27742539/does-bleomycin-lung-toxicity-increase-the-risk-of-radiation-pneumonitis-in-hodgkin-lymphoma
#16
Zeinab Abou Yehia, George N Mikhaeel, Grace Smith, Chelsea C Pinnix, Sarah A Milgrom, Chad Tang, Wen Jiang, Michelle A Fanale, Yasuhiro Oki, JoAnn H Shank, Trisha Horace, Jay Reddy, Mani Akhtari, Jillian R Gunther, Tina Suki, Pamela K Allen, Shryll Turner, Osama Mawlawi, Bouthaina S Dabaja
PURPOSE: Bleomycin pulmonary toxicity (BPT) is a well-known complication of treatment in patients with Hodgkin lymphoma (HL). We undertook the present study to investigate the risk of radiation pneumonitis (RP) in the setting of BPT and to determine the need for delay or omission of radiation therapy (RT) in these patients. METHODS AND MATERIALS: We identified 123 HL patients treated with ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) followed by RT to the chest from January 2009 to December 2014...
December 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27733075/the-number-of-tumor-infiltrating-t-cell-subsets-in-lymph-nodes-from-patients-with-hodgkin-lymphoma-is-associated-with-the-outcome-after-first-line-abvd-therapy
#17
Sara Alonso-Álvarez, Maria Belén Vidriales, Maria Dolores Caballero, Oscar Blanco, Noemí Puig, Alejandro Martin, Maria Jesús Peñarrubia, Esther Zato, Josefina Galende, Abelardo Bárez, Miguel Alcoceba, Alberto Orfão, Marcos González, Ramón García-Sanz
Prognostic factors in Hodgkin lymphoma (HL) still fail to accurately identify high-risk patients. Tumor microenvironment in HL is a current focus of research for risk definition but few studies have focused on infiltrating lymphocytes. Here, we analyzed the number of tumor infiltrating lymphocytes by flow cytometry in diagnostic biopsies from 96 HL homogeneously treated patients with ABVD with or without radiotherapy. Most lymph node cells were lymphocytes (90 ± 17), with a median T/B/NK distribution of 74%/26%/0...
October 12, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27692305/the-combined-role-of-biomarkers-and-interim-pet-scan-in-prediction-of-treatment-outcome-in-classical-hodgkin-s-lymphoma-a-retrospective-european-multicentre-cohort-study
#18
Claudio Agostinelli, Andrea Gallamini, Luisa Stracqualursi, Patrizia Agati, Claudio Tripodo, Fabio Fuligni, Maria Teresa Sista, Stefano Fanti, Alberto Biggi, Umberto Vitolo, Luigi Rigacci, Francesco Merli, Caterina Patti, Alessandra Romano, Alessandro Levis, Livio Trentin, Caterina Stelitano, Anna Borra, Pier Paolo Piccaluga, Stephen Hamilton-Dutoit, Peter Kamper, Jan Maciej Zaucha, Bogdan Małkowski, Waldemar Kulikowski, Joanna Tajer, Edyta Subocz, Justyna Rybka, Christian Steidl, Alessandro Broccoli, Lisa Argnani, Randy D Gascoyne, Francesco d'Amore, Pier Luigi Zinzani, Stefano A Pileri
BACKGROUND: Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease. METHODS: We enrolled 208 patients with classical Hodgkin's lymphoma and treated with ABVD (training set), from Jan 1, 2002, to Dec 31, 2009, and validated the results in a fully matched independent cohort of 102 patients with classical Hodgkin's lymphoma (validation set), enrolled from Jan 1, 2008, to Dec 31, 2012...
October 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27688147/bleomycin-induced-skin-toxicity-is-it-always-flagellate-erythema
#19
Shailendra Prasad Verma, Arunkumar Subbiah, Vinod Kolar Vishwanath, Tarun Kumar Dutta
Bleomycin-induced skin toxicity is a rare and unique complication. We report a 35-year-old man with nodular lymphocytic predominant Hodgkin's lymphoma, stage IVB, who was started on adriamycin, bleomycin, vinblastin and dacarbazine (ABVD) chemotherapy. He developed pruritic hyperpigmented, patchy skin lesions on the neck, back, chest and thighs after IA cycle of ABVD chemotherapy. Lesions were not typical flagellate rash but hyperpigmented, patchy and mildly pruritic lesions over the trunk and proximal extremities...
2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27675801/treatment-of-early-stage-unfavorable-hodgkin-lymphoma-efficacy-and-toxicity-of-4-versus-6-cycles-of-abvd-chemotherapy-with-radiation
#20
J R Gunther, M Fanale, J Reddy, M Akhtari, G L Smith, C C Pinnix, S A Milgrom, Z Abou Yehia, E M Osborne, O R Mawlawi, P K Allen, B Dabaja
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
71275
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"